Anifrolumab Benefits Seen in Second Lupus RCT Analysis
The monoclonal anifrolumab improved BICLA responses, reduced use of prednisone, and improved skin disease in patients with SLE, particularly those with high type 1 interferon gene signatures.
Related Articles
Probiotic Mixture Reduces Fever Duration in Children With Upper Respiratory Infections by 2 Days
A probiotic mixture containing three specific probiotic bacterial strains reduces fever duration by 2 days in children with upper respiratory tract infections.
Can Six Shots a Year Keep Hemophilia Bleeding Away?
Novel antithrombin-based dosing regimen enhances safety and efficacy in hemophilia treatment.
Radiation Oncology Practice Consolidation: A Growing Trend?
The number of radiation oncology practices has declined as consolidation trends push radiation oncologists toward fewer, larger practices, a new study found.
Three-year-Old Has Nightly Fever, Lymphadenopathy, and Rash
A 3-year-old boy presents to the ED with 10 days of nightly fever. He also has cervical lymphadenopathy and an intermittent erythematous macular rash. Can…
Do We Know Enough About Assisted Dying Drugs?
Amid the ethical and legal arguments, a fundamental question remains: How much do we truly understand about the drugs used in these end-of-life procedures?
Time-Restricted Mediterranean Diet Shows Promise for MASLD
The Mediterranean diet, combined with early time-restricted feeding, reduces A1c levels and insulin resistance in patients with MASLD and overweight or obesity.
#DiedSuddenly Was BS: Why Did We Believe It?
A hashtag that gained a lot of traction during the COVID-19 pandemic is, thankfully, in decline, but can we avoid buying into such nonsense again?
Managing Familial Hypercholesterolemia in Primary Care
Familial hypercholesterolemia is often diagnosed late, and patients with the condition are significantly undertreated.
Increasing, Persistent PSA Levels Linked to Higher All-Cause Mortality
Investigators assess the impact of increasing persistent PSA levels on prostate cancer–specific mortality and all-cause mortality risk.
FLAGging Down Updates in Cutaneous Melanoma: Investigating the Role of LAG-3
Join this dynamic expert dialogue about the latest data on lymphocyte activating gene 3 (LAG-3) inhibitors in advanced cutaneous melanoma.